Soluble CD46 as a diagnostic marker of hepatic steatosisResearch in context

Summary: Background: The increasing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) incurs substantial morbidity, mortality and healthcare costs. Detection and clinical intervention at early stages of disease improves prognosis; however, we are currently limited by a...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Florian Bitterer, Paul Kupke, Akinbami Adenugba, Katja Evert, Gunther Glehr, Paloma Riquelme, Lena Scheibert, Giulia Preverin, Christina Böhm, Matthias Hornung, Hans J. Schlitt, Jürgen J. Wenzel, Edward K. Geissler, Niloufar Safinia, James A. Hutchinson, Jens M. Werner
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Elsevier 2024-06-01
סדרה:	EBioMedicine
נושאים:	Hepatic steatosis Fatty liver disease Predictive marker Innate immunity
גישה מקוונת:	http://www.sciencedirect.com/science/article/pii/S2352396424002196
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!